The standard manufacturing workflow for approved CAR T cell therapies involves isolating a patient’s own T cells, introducing a CAR-encoding gene, expanding the cells, and reinfusing them. Viral vectors achieve stable CAR expression but carry well-known liabilities: the risk of insertional mutagenesis, potential immunogenicity, limited cargo capacity, labor-intensive production, and costs that restrict broader clinical access. Electroporation, the clinical standard for mRNA transfection of T cells, requires specialized equipment and compromises membrane integrity, reducing viability and altering cellular physiology in ways that demand additional safety evaluation.

Messenger RNA offers an attractive middle path. Because it does not integrate into the genome and drives only transient CAR expression, it confers a self-limiting safety profile, confining receptor expression to a defined window of days. mRNA-based CAR T cells have already shown efficacy against acute lymphoblastic leukemia, melanoma, and Hodgkin lymphoma comparable to virally transduced cells. The challenge has always been delivery: naked mRNA is inherently unstable and cannot cross the cell membrane on its own, so a carrier is essential.

The research team, led by investigators at Shanghai University and the Shanghai Cell Therapy Group, synthesized a library of eight novel ionizable lipids as structural analogs of previously reported candidates effective in immune cell transfection. Each lipid was formulated into a nanoparticle by microfluidic mixing with a fixed excipient composition: cholesterol for membrane integrity and stability, the phospholipid DOPE to facilitate endosomal escape, and the PEG-lipid DMG-PEG2000 to confer colloidal stability and reduce nonspecific uptake. Holding the excipient ratios constant allowed the researchers to isolate the effect of the ionizable lipid head group during screening.

Dynamic light scattering and RiboGreen assays confirmed that all eight formulations were monodisperse, with Z-average diameters between 79.6 and 97.2 nanometers, polydispersity indices between 0.107 and 0.180, and mRNA encapsulation efficiencies above 95 percent. When screened in the murine dendritic cell line DC2.4 and in activated human peripheral blood mononuclear cells using eGFP mRNA, four of the eight candidates transfected more than 90 percent of DC2.4 cells, and lipid 6 emerged as the clear leader, delivering the highest eGFP positivity rates and mean fluorescence intensity and surpassing the clinically validated benchmark lipid ALC-0315.

In vivo validation using firefly luciferase mRNA in mice showed that lipid 6 elicited significantly higher luciferase expression than the benchmark lipids SM-102 and ALC-0315 at the six-hour time point for both intravenous and intramuscular routes. Intravenous injection produced the strongest systemic signal, whereas intramuscular administration yielded a more prolonged, localized signal that remained detectable at the injection site 72 hours after dosing. The researchers then systematically optimized the formulation using a design-of-experiments approach, screening 26 formulations across two rounds by varying the stoichiometry of the four LNP components. Both the ionizable lipid and DMG-PEG2000 concentrations exerted the strongest influence on transfection outcomes, and the team selected a formulation with reduced PEG-lipid content to minimize potential immunogenicity.

Titrating the nitrogen-to-phosphate ratio revealed that eGFP positivity increased with the ratio and plateaued at a value of 5, while mean fluorescence intensity peaked at a ratio of 10 before declining. Supplementing the transfection with recombinant APOE4 boosted efficiency, which plateaued at 1 microgram per milliliter, and an mRNA dose of 150 nanograms per 500,000 cells proved saturating. Under the finalized protocol, more than 90 percent of primary human T cells, natural killer cells, and dendritic cells expressed eGFP, and tumor-infiltrating lymphocytes isolated from hepatocellular carcinoma tissues exceeded 97 percent positivity. Both activated and unactivated T cells were transfected efficiently, at greater than 95 percent and greater than 80 percent positivity respectively. Storage testing showed the nanoparticles remained remarkably stable at 4 degrees Celsius, maintaining high cell viability and roughly 100 percent eGFP expression for up to 110 days, but performance collapsed within two weeks at 25 or 37 degrees Celsius.

The pivotal demonstration came when the team encapsulated mRNA encoding a MUC1-targeting CAR in lipid 6. Roughly 90 percent of transfected T cells expressed the CAR protein 24 hours after transfection, with CD4-positive and CD8-positive subset ratios unchanged and no significant upregulation of the exhaustion markers PD-1, LAG-3, or TIM-3. In real-time cytotoxicity assays, the engineered cells showed significantly enhanced killing of MUC1-expressing MDA-MB-468 breast cancer cells and SKOV3 ovarian cancer cells at every effector-to-target ratio tested, accompanied by markedly increased secretion of the Th1-type cytokines IL-2, TNF-alpha, and IFN-gamma. Longitudinal tracking showed CAR expression peaked at 24 hours and declined to below 5 percent by day 4, yet the cells retained significantly higher tumor-killing capacity than controls at each of the first three days after transfection, all while maintaining normal proliferation and viability.

Transcriptomic sequencing of lipid 6-transfected T cells reinforced the mechanistic picture. Gene Ontology enrichment pointed to upregulation of gene sets involved in transmembrane transport, membrane dynamics, cell junction organization, and intracellular trafficking, consistent with enhanced endosomal escape and cytosolic mRNA release. Kyoto Encyclopedia of Genes and Genomes pathway analysis showed robust activation of cytokine-cytokine receptor interactions, T cell receptor signaling, chemokine signaling, and Th1/Th2 differentiation pathways, indicating that the delivery process triggered physiological T cell activation without exhaustion or aberrant inflammatory signaling. Notably, unlike liver-tropic lipid nanoparticles that depend on APOE-mediated uptake, lipid 6 appears to operate in immune cells through alternative endocytic pathways, though the precise intracellular trafficking and endosomal escape mechanisms remain to be fully elucidated.

The authors are candid about the study’s limitations. All cellular assessments were confined to in vitro experiments, so long-term antitumor efficacy, biodistribution, and biosafety in tumor-bearing animal models remain unverified. Only a MUC1-targeted CAR was examined, leaving the platform’s generality across other tumor antigens untested, and scalable GMP-level production processes have not yet been established. The transient nature of mRNA expression, while a safety advantage, may also limit therapeutic persistence in solid tumor microenvironments. Even so, the work establishes a rationally designed, nonviral platform that overcomes the insertional mutagenesis risks, cellular damage, and prohibitive costs associated with viral vectors and electroporation, and it points toward a future in which CAR T cells and other engineered immune cell therapies can be manufactured more safely, more scalably, and more affordably.

Subject of Research: Lipid nanoparticle-mediated mRNA delivery for nonviral CAR T cell engineering

Article Title: Lipid-based mRNA chimeric antigen receptor T cells for enhanced in vitro antitumor activity

Article References: Gao, H., Fang, Y., Tian, Z., Guo, C., Wang, P., Liu, T., Sun, Y., Zhang, P., & Qian, Q. (2026). Lipid-based mRNA chimeric antigen receptor T cells for enhanced in vitro antitumor activity. iScience, 29(10), Article 117390. https://doi.org/10.1016/j.isci.2026.117390

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117390

Keywords: CAR T cells, lipid nanoparticles, mRNA delivery, ionizable lipids, immunotherapy, nonviral gene delivery, MUC1, T cells, endosomal escape, cancer therapy, transient expression, ex vivo engineering

The structural logic of MUC1 explains both its normal function and its malignant potential. The MUC1 gene, located on chromosome 1q21-24, encodes a single polypeptide of 120 to 225 kilodaltons that balloons to 250 to 500 kilodalts after glycosylation. Its extracellular region contains between 20 and more than 100 tandem repeats of a 20-amino-acid sequence, each repeat carrying five O-glycosylation sites, producing a glycocalyx that extends hundreds of nanometers beyond the cell surface. Critically, the protein undergoes autoproteolysis within its SEA domain, cleaving at a GSVVV motif into two subunits that remain associated as a non-covalent heterodimer: MUC1-N, the sheddable, sugar-laden protective arm, and MUC1-C, a compact transmembrane unit with a 58-amino-acid extracellular domain, a 28-amino-acid membrane anchor, and a 72-amino-acid cytoplasmic tail that functions as the molecule’s oncogenic brain. In normal epithelia, the complex sits strictly at the apical membrane; in tumors, it spreads across the entire cell surface and into the cytoplasm, its O-glycans truncated into tumor-associated forms such as Tn, sTn, TF, and sTF.

MUC1-C is where the real molecular action happens. Its extracellular domain carries an NLT motif whose N-glycans recruit galectin-3, which in turn bridges MUC1-C to EGFR and other receptor tyrosine kinases at the membrane. Its cytoplasmic tail bristles with 12 documented and putative phosphorylation sites that serve as substrates for EGFR, Src-family kinases, ABL, GSK3β, and ZAP70, creating docking platforms for effectors such as PI3K, SRC, and GRB2. A CQC motif near the membrane, activated by reactive oxygen species, drives MUC1-C oligomerization and directs the protein to the nucleus via importin-β and to mitochondria via HSP70/90 chaperones, where it blocks the intrinsic apoptotic pathway. In the nucleus, MUC1-C binds β-catenin and TCF4 to occupy the CCND1 promoter, recruits p300 to acetylate histone H3K27, and interacts directly with p53, IKKα, IKKβ, and RelA, placing it at the command posts of the Wnt, p53, and NF-κB pathways simultaneously.

Two auto-inductive feedback loops give this signaling web its self-sustaining, pathological persistence. MUC1-C binds JAK1 and STAT3 directly, promoting STAT3 phosphorylation; activated STAT3 then binds the MUC1 promoter, cranking out more MUC1-C in a loop that is transient during normal inflammatory responses but constitutively locked on in carcinomas. A parallel loop operates with NF-κB, which MUC1-C activates both by stimulating the IKK complex and by physically blocking NF-κB’s inhibitor IκBα. Beyond these canonical circuits, the review highlights MUC1-C’s emerging role as an epigenetic master regulator: the protein induces the Yamanaka pluripotency factors OCT4, SOX2, KLF4, and MYC, binds the Polycomb marks H2A K119 ubiquitylation and H3K27 methylation, and reshapes chromatin accessibility at JUN/AP-1-regulated enhancers, thereby enforcing the lineage plasticity and stem-like state that make cancer cells so hard to eradicate.

The downstream consequences for anti-tumor immunity are stark. MUC1-C’s cytoplasmic tail sustains a JAK1-STAT1-IRF1 transcriptional axis that upregulates IDO1 and COX2/PTGES, depleting tryptophan, accumulating kynurenine, and generating prostaglandin E2, together halting CD8-positive T-cell cycling and pushing regulatory T-cell differentiation. MUC1-C also delivers mutant p53 and β-catenin to the CTGF promoter, unleashing connective tissue growth factor that recruits cancer-associated fibroblasts and deposits a physical collagen barrier. Analyses of TCGA, METABRIC, and single-cell datasets consistently show that MUC1-high tumors are depleted of cytotoxic T cells, Th1 helpers, B cells, and M1 macrophages while enriched in Tregs, myeloid-derived suppressor cells, and M2-polarized tumor-associated macrophages. Even at the glycan level, sTn-decorated MUC1 engages Siglec-9 on myeloid cells to trigger a calcium-MEK-ERK program that completes macrophage polarization and renders tumors refractory to PD-1 blockade, effectively converting an immunological hotbed into what the authors describe as an ice cave.

Disease-specific evidence reinforces the breadth of this mechanism. In breast cancer, high MUC1 mRNA predicts reduced overall, disease-free, and recurrence-free survival; MUC1-C interacts with estrogen receptor alpha to drive tamoxifen resistance, forms a self-sustaining loop with TWIST1 that underlies paclitaxel resistance, and cooperates with STAT1 in roughly 15 percent of primary breast tumors, a co-expression pattern linked to poor outcomes. In non-small cell lung cancer, MUC1-C drives acquired resistance to osimertinib by sustaining ERK and AKT signaling through EGFR/MET heterodimerization, occupies the CD274 promoter to induce PD-L1, and represses immune genes such as TLR9 and IFN-γ through ZEB1. In pancreatic ductal adenocarcinoma, where MUC1 is overexpressed in more than 60 percent of cases, the protein stabilizes HIF-1α, accelerates glycolysis and pyrimidine biosynthesis, and accumulates endogenous dCTP that directly antagonizes gemcitabine, while also suppressing BRCA1 and blunting radiosensitivity.

The oncogenic reach extends into blood cancers and chronic inflammatory disease. MUC1 is overexpressed specifically in acute myeloid leukemia stem cells, where it stabilizes both wild-type and mutant FLT3 receptors and activates the AKT/ERK/STAT5 axis; the peptide inhibitor GO-203 selectively eliminates these stem cells while sparing normal hematopoiesis. In chronic myeloid leukemia, MUC1 physically stabilizes the Bcr-Abl fusion protein and maintains imatinib resistance, while in multiple myeloma, aberrantly glycosylated MUC1 appears on 73 percent of malignant plasma cells and drives the WNT/β-catenin-TCF4-MYC survival program alongside redox balance maintained with TIGAR. Outside oncology, loss of MUC1 in chronic obstructive pulmonary disease correlates with steroid resistance, aberrant MUC1 glycosylation in ulcerative colitis promotes colitis-associated colorectal cancer, and frameshift mutations in the VNTR region cause autosomal dominant tubulointerstitial kidney disease through endoplasmic reticulum stress.

Therapeutically, the field has learned hard lessons but is now fielding a far more sophisticated arsenal. Only two MUC1-targeted drugs have reached phase III trials, the liposomal peptide vaccine Tecemotide and the poxviral vector TG4010, and both failed to improve survival, a result attributed in part to MUC1’s poor intrinsic immunogenicity and the redundancy of the pathways it controls. The current generation of approaches is more precise: monoclonal antibodies such as DMB5F3 against the SEA domain and GGSK-1/30, whose zirconium-89-labeled form achieved over 50 percent injected dose per gram tumor uptake with 96.5 percent diagnostic specificity in PET imaging; antibody-drug conjugates including 3D1-MMAE, which eradicated MUC1-positive lung and breast tumors in transgenic mice without toxicity; CAR-T cells engineered against the tumor-specific Tn-glycoform of MUC1, which spare normal epithelium; armored allogeneic CAR constructs with PD1 and TGFBR2 knockout and IL-12 insertion; oncolytic adenoviruses encoding MUC1-CD3 bispecific T-cell engagers; and RNA interference delivered by MUC1-aptamer-tethered nanoparticles.

The review’s authors are candid about the remaining obstacles. Because MUC1-C sits at the hub of so many compensatory networks, single-agent inhibition invites bypass signaling through AXL, MET, or downstream PI3K and MEK pathways, and chronic blockade can push cells toward stem-like or neuroendocrine phenotypes through epigenetic remodeling. The most promising path, they argue, is rational combination and sequencing: pairing MUC1-C inhibitors with PI3K/AKT/mTOR blockade, PD-1 antibodies, or epigenetic drugs such as decitabine, or using MUC1-C inhibition as a priming step to reverse epithelial-mesenchymal transition before conventional chemotherapy or checkpoint inhibitors. Preclinical combination studies already show dramatic gains, with a MUC1-MBP vaccine plus anti-PD-1 raising tumor clearance in mice from 20 to 80 percent. With nanodelivery systems, cell-carrier platforms, and MUC1-triggered smart materials now entering the design space, the molecule once dismissed after two failed phase III trials is being repositioned as what may become one of oncology’s most consequential pan-cancer targets, provided that mechanistic depth and rigorous clinical validation keep pace with the enthusiasm.

Subject of Research: The role of the MUC1 mucin, particularly its MUC1-C subunit, in oncogenic signaling, immune evasion, and targeted cancer therapy development

Article Title: MUC1 in cancer

Article References: Qian, K., Zhang, Y., Zhou, Q., Zhou, J., Wu, X., Zhu, J., Pan, Y., Wu, Z., Li, S., Lin, Y., Lyu, F., Chen, S., & Sun, H. (2026). MUC1 in cancer. Holistic Integrative Oncology, 5(1), Article 32. https://doi.org/10.1007/s44178-026-00257-w

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00257-w

Keywords: MUC1, MUC1-C, cancer biology, oncogenic signaling, immune evasion, immunotherapy, CAR-T cells, antibody-drug conjugates, cancer vaccines, drug resistance, epigenetic reprogramming, tumor microenvironment

The research, led by Yanjun Ge and Haiyan Zhu of Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, together with colleagues at Wenzhou Medical University and OriCell Therapeutics, set out to answer a deceptively simple question: what does the tumor cell surface actually look like after MUC1α has been shed? Most MUC1-targeted CAR-T programs have focused on the shed-prone alpha subunit, particularly tumor-associated glycoforms of the variable number tandem repeat region. But when MUC1α is cleaved, it leaves behind a membrane-retained truncated MUC1β stub, and that stub exposes neoepitopes that were previously hidden or inaccessible. These shedding-exposed epitopes have received comparatively little attention from the CAR-T field, and the team suspected they could be exploited.

To find an antibody against truncated MUC1β, the researchers turned to an unusual but increasingly popular source: alpaca immune antibody libraries. Camelid antibodies are prized in antibody engineering because their single-chain variable fragments are compact, stable, and often recognize clefts or unusual conformations that conventional antibodies miss. By screening immune libraries from alpacas, the team isolated a binder specific to the truncated MUC1β form. That single-chain variable fragment became one of the two recognition domains in what the researchers call a biparatopic CAR, a construct carrying two different antigen-binding modules on a single chimeric antigen receptor.

Before building the therapeutic cells, however, the team needed to know whether the target landscape in actual patient tumors justified the design. Using multiplex immunohistochemistry with two antibodies, one recognizing truncated MUC1β and another recognizing tumor-associated MUC1α glycoforms, they mapped the distribution of MUC1 forms in situ in ovarian cancer tissue. The finding was striking: MUC1 commonly exists in a partially shed state, with full-length MUC1 and truncated MUC1β co-occurring within the same tumor tissue. In other words, shedding is not an all-or-nothing event that uniformly strips MUC1α from every cell. Instead, it creates a mosaic in which some cells display intact MUC1, some display only the truncated beta stub, and many display both. Any therapy that recognizes only one of these states would leave gaps in coverage, and those gaps are precisely where antigen escape could begin.

The biparatopic CAR-T cells were designed to close those gaps. In laboratory tests against ovarian cancer cell lines, the dual-target cells efficiently recognized and killed MUC1-positive tumor cells regardless of how the antigen was presented, whether as full-length MUC1 alone, truncated MUC1β alone, or both forms together. Monospecific CAR-T cells, by contrast, killed only those target cells displaying their corresponding epitope, leaving the rest untouched. This broader target coverage is the core conceptual advance of the study: rather than betting everything on a single epitope that shedding can erase, the biparatopic design hedges across both the intact and the shed forms of the antigen, so that the very act of MUC1α shedding creates a new target rather than destroying an old one.

The data also revealed a quantitative benefit beyond simple coverage. Against tumor cells co-expressing full-length MUC1 and truncated MUC1β, the biparatopic CAR-T cells showed higher cytotoxicity and greater cytokine release than their monospecific counterparts. This pattern is consistent with the idea that engaging two epitopes on the same cell provides stronger and more sustained activation signals, a phenomenon that has been observed in other biparatopic and dual-target CAR systems. The engineering principle is straightforward: when a CAR-T cell can dock at two points on its target antigen, the probability of productive activation rises, and the cell is less likely to be fooled by partial loss of one epitope.

One of the most clinically consequential findings concerns soluble MUC1 in the tumor microenvironment. Shed MUC1α circulates as a soluble antigen, and one clinically familiar readout of this shedding is CA153, cancer antigen 153, a marker routinely measured in the serum of patients with MUC1-expressing carcinomas. Soluble antigen is a classic saboteur of CAR-T therapy: it can bind the CAR before the cell ever reaches the tumor, triggering exhaustion or simply soaking up the receptor. The researchers therefore tested whether soluble CA153 would impair the killing ability of their biparatopic CAR-T cells. It did not. Not only was killing preserved, but exposure to soluble CA153 actually induced CAR-T activation. The dual-target design appears to have converted the soluble antigen from a decoy into a stimulus, although the authors note that the precise consequences of chronic activation by circulating antigen in patients will require careful clinical evaluation.

The therapeutic promise held up in living systems. In ovarian tumor xenograft models, the MUC1 biparatopic CAR-T cells exhibited superior tumor control compared with monospecific controls, maintaining pressure on tumors even as antigen presentation varied. Perhaps more importantly for translational relevance, the team evaluated the cells against patient-derived tumor-like cell clusters, three-dimensional cultures established directly from ovarian cancer patients that preserve more of the heterogeneity and architecture of real tumors than standard cell lines. Against these patient-derived clusters, the biparatopic cells again showed enhanced activity, suggesting that the approach can perform against the messy, heterogeneous antigen landscape that actual clinical CAR-T products will face.

The study’s framing of partial MUC1α shedding as a prevalent and exploitable feature of ovarian cancer is what elevates it beyond a single construct report. If multiplex immunohistochemistry can confirm in a given patient’s tumor that both full-length MUC1 and truncated MUC1β are present, clinicians would have a rational basis for selecting a biparatopic product, and the shed form itself becomes a biomarker of target availability rather than a warning sign of escape. The work also highlights a broader lesson for the CAR-T field: targets that shed are not necessarily poor targets, provided the receptor is engineered to recognize what shedding leaves behind. Several other tumor-associated antigens, including epidermal growth factor receptor variants and other mucins, are known to undergo proteolytic cleavage, and the biparatopic logic demonstrated here could in principle be adapted to them.

Caveats remain, as they always do at this stage. The work rests on xenograft models and ex vivo patient-derived clusters rather than human trials, and questions of safety, persistence, and the behavior of the cells in the presence of the high circulating MUC1 levels seen in some patients will need to be answered in carefully designed clinical studies. The patent application filed by several of the authors signals commercial interest in moving the construct toward the clinic. Still, the study establishes a clear proof of principle: by targeting both the intact antigen and the truncated remnant that shedding exposes, CAR-T cells can be built that treat antigen loss not as an obstacle but as an invitation. For a disease like ovarian cancer, where relapse and immune escape are the norm, that inversion of the problem may prove to be the study’s most lasting contribution.

Subject of Research: Biparatopic CAR-T cell therapy targeting MUC1 shedding to overcome antigen escape in ovarian cancer

Article Title: Biparatopic CAR-T cells targeting full-length MUC1 and truncated MUC1β circumvent MUC1α shedding in ovarian cancer

Article References: Ge, Y., Zhang, Y., Li, X., Zhao, J., Wang, H., Yang, S., He, X., & Zhu, H. (2026). Biparatopic CAR-T cells targeting full-length MUC1 and truncated MUC1β circumvent MUC1α shedding in ovarian cancer. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09032-x

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09032-x

Keywords: ovarian cancer, CAR-T cell therapy, MUC1, antigen shedding, biparatopic CAR, immunotherapy, MUC1β, CA153, tumor escape, alpaca antibodies, patient-derived tumor models, Journal of Translational Medicine

The work addresses one of the most stubborn problems in modern oncology: translating the spectacular success of CAR T cell therapy in blood cancers into solid tumors. Since the first CAR T products received regulatory approval, patients with certain leukemias and lymphomas have benefited from engineered immune cells that can seek out and destroy malignant cells bearing a specific molecular marker. Solid tumors, however, have proven far more difficult targets. They deploy hostile microenvironments, suppressive signaling pathways, and heterogeneous surface antigens that blunt the activity of infused cells. Breast cancer, the leading cause of cancer-related mortality globally, exemplifies these challenges, and the study’s authors frame their work as a direct response to this unmet clinical need.

The choice of target antigen is central to the strategy. Mucin 1 is a large, heavily glycosylated protein that normally lines the apical surfaces of epithelial tissues, where it plays protective roles. In tumor cells, however, glycosylation patterns break down, producing a hypoglycosylated, tumor-associated form of MUC1 that is exposed in ways the normal protein is not. This aberrant presentation makes MUC1 an attractive target for T cell-based therapies, because the abnormal form is largely absent from normal tissues, potentially widening the therapeutic window. The team, led by researchers at the Siriraj Center of Research Excellence for Cancer Immunotherapy at Mahidol University’s Faculty of Medicine Siriraj Hospital, set out to establish both the clinical relevance of MUC1 and the superiority of a fourth-generation receptor design against it.

To establish that relevance, the investigators turned to The Cancer Genome Atlas, a large public repository of genomic and clinical data. Their analysis revealed that high MUC1 expression in breast cancer is associated with reduced overall survival and reduced disease-free survival, positioning MUC1 not merely as a target but as a potential prognostic biomarker that could help identify patients with aggressive disease. The genomic signal was then corroborated at the protein level. Using immunohistochemical staining on patient tissue samples, the researchers found that 57 of 59 breast cancer samples, or 96.6 percent, were positive for MUC1. High MUC1 expression was also confirmed across breast cancer cell lines used in the laboratory experiments, ensuring that the preclinical models faithfully reflected the antigen landscape of human tumors.

With the target validated, the team constructed and compared three CAR designs. Second-generation receptors, the workhorse of approved therapies, combine an antigen-binding domain with a single intracellular costimulatory module, typically CD28 or 4-1BB, fused to the CD3 zeta signaling chain. Third-generation receptors add a second costimulatory domain in an effort to amplify activation. Fourth-generation receptors go further, incorporating an additional genetic payload, often encoding a cytokine or other immune-enhancing factor, that is expressed upon antigen engagement, effectively turning the engineered cell into a localized delivery system for immune stimulation. The αM.CAR4 construct paired an anti-MUC1 single-chain variable fragment, the HMFG2 sequence generously provided by Professor John Maher, with this augmented signaling architecture.

The comparative evaluation began at baseline, where the fourth-generation cells displayed immunophenotypes broadly comparable to those of the second- and third-generation counterparts, indicating that the added complexity had not fundamentally altered the cells’ resting state. The differences emerged dramatically after antigen exposure. When the engineered cells encountered MUC1-expressing tumor cells, the αM.CAR4 T cells demonstrated significantly the highest proliferation among the three designs while simultaneously exhibiting the lowest exhausted phenotype, a statistically significant advantage at the p less than 0.05 threshold. T cell exhaustion, a dysfunctional state marked by inhibitory receptor upregulation and loss of effector function, is a major cause of CAR T failure in solid tumors, making this resilience particularly noteworthy.

Cytotoxic performance told a similar story. The fourth-generation cells required markedly lower doses to achieve higher levels of tumor cell killing, a difference significant at the p less than 0.01 level, suggesting that each αM.CAR4 cell packs greater lethal capacity per encounter. Consistent with this, the cells produced significantly higher levels of cytotoxic effector proteins, the molecular weapons, including granzymes and perforin, that engineered T cells deploy to punch holes in tumor cell membranes and trigger programmed cell death. In three-dimensional spheroid models, which better mimic the dense architecture of real tumors than flat cell cultures, the αM.CAR4 cells induced rapid spheroid destruction, again reaching statistical significance at p less than 0.05. Together, these assays paint a picture of a receptor design that not only survives antigen stimulation but converts it into sustained, potent anti-tumor activity.

The implications extend in two directions. Clinically, the findings support MUC1 expression as a potential prognostic biomarker in breast cancer, offering a molecular handle for risk stratification that could complement existing markers. Therapeutically, the results argue that fourth-generation CAR architecture may be the key to unlocking MUC1-directed immunotherapy for solid tumors, where earlier generations have struggled. Because the tumor-associated form of MUC1 is largely absent from normal tissues, the approach may also carry a favorable safety profile compared with targets shared between healthy and malignant cells, though on-target off-tumor effects against epithelial tissues will require careful evaluation in future studies.

The researchers are careful to position this work as a foundation rather than a finished therapy. Their summary explicitly states that αM.CAR4 T cells represent a promising alternative strategy for breast cancer immunotherapy and that the findings support further development and evaluation of MUC1-targeting CAR T cells in pre-clinical and clinical studies. The road from laboratory bench to approved treatment is long, involving manufacturing optimization, safety pharmacology, dose escalation, and ultimately randomized clinical trials. Yet the convergence of near-universal MUC1 expression in patient samples, a clear survival correlation from genomic data, and demonstrable functional superiority of the fourth-generation design gives the field a coherent rationale for advancing this approach.

The study also reflects a broader international and collaborative effort. The work was conducted by teams spanning Mahidol University’s Siriraj Hospital in Bangkok, including the Division of Head-Neck and Breast Surgery, the Department of Pathology, and the Department of Immunology, in partnership with Kumamoto University in Japan, where co-author Seiji Okada leads the Division of Hematopoiesis at the Joint Research Center for Human Retrovirus Infection. Many of the investigators are members of the Thailand Hub of Talents in Cancer Immunotherapy, supported by the National Research Council of Thailand, with additional funding from Mahidol University and Siriraj Research Fund. As breast cancer continues to claim lives worldwide despite advances in surgery, chemotherapy, and targeted agents, engineered immune cells capable of recognizing the aberrant molecular signature of malignancy, and sustaining their attack where earlier designs falter, offer a compelling glimpse of where cancer immunotherapy may be headed next.

Subject of Research: Development of fourth-generation chimeric antigen receptor T cells targeting mucin 1 for enhanced immunotherapy of breast cancer

Article Title: Fourth-generation chimeric antigen receptor T cells targeting mucin 1 for enhanced anti-tumor activity against breast cancer

Article References: Supimon, K., Sangsuwannukul, T., Sawasdee, N., Choomee, K., Natungnuy, K., Nganrungreung, S., Tripatara, P., Jirawatnotai, S., Sa-nguanraksa, D., Warnnissorn, M., Thuwajit, C., Okada, S., Junking, M., & Yenchitsomanus, P.-T. (2026). Fourth-generation chimeric antigen receptor T cells targeting mucin 1 for enhanced anti-tumor activity against breast cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04557-y

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04557-y

Keywords: breast cancer, CAR T cells, chimeric antigen receptor, mucin 1, cancer immunotherapy, MUC1, fourth-generation CAR, T cell exhaustion, tumor immunology, prognostic biomarker, immunotherapy, solid tumors